Compare RBCAA & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | CDNA |
|---|---|---|
| Founded | 1974 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1998 | 2007 |
| Metric | RBCAA | CDNA |
|---|---|---|
| Price | $96.46 | $45.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 97.7K | ★ 1.1M |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.77 | ★ 2.13 |
| Revenue | ★ $417,495,000.00 | $48,324,000.00 |
| Revenue This Year | $3.93 | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | $125.66 | ★ $21.77 |
| Revenue Growth | 8.50 | ★ 18.93 |
| 52 Week Low | $63.97 | $11.27 |
| 52 Week High | $102.22 | $49.76 |
| Indicator | RBCAA | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 63.69 |
| Support Level | $88.24 | $16.70 |
| Resistance Level | $102.11 | $49.76 |
| Average True Range (ATR) | 2.26 | 2.29 |
| MACD | -0.68 | -0.39 |
| Stochastic Oscillator | 23.11 | 70.31 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.